法特壶腹腺癌 (AAC) 是一种罕见的恶性肿瘤，具有由各种组织学亚型产生的异质性肿瘤，需要新的治疗策略。鉴于表皮生长因子受体 (EGFR)、人表皮生长因子受体 2 (HER2) 和 c-Met 作为药物靶点的潜力，本研究检查了 AAC 中的表皮生长因子受体 (EGFR)、人表皮生长因子受体 2 (HER2) 和 c-Met 表达。在 87 例接受根治性切除的患者中，EGFR 过表达占 87.4%，HER2 过表达占 11.5%，c-Met 过表达占 50%。 EGFR 过表达在胰胆亚型中更为常见 (p = 0.018)，并且与较高的组织学分级相关 (p = 0.008)。 HER2 与临床病理特征无关，而 c-Met 在淋巴结阴性组中更常见 (p = 0.004)，并且经常与 EGFR 共表达 (p = 0.049)。与 EGFR 阴性患者相比，EGFR 阳性患者的无病生存率（HR = 2.89；95% CI，1.35-6.20；p = 0.061）和总生存率（HR = 6.89；95% CI，2.94-16.2；p = 0.026）较差患者。 HER2 阳性 AAC 显示出生存期缩短的趋势，尽管没有统计学意义，并且 c-Met 对生存结果没有影响。在全身性疾病的情况下，生存结果并不根据 EGFR、HER2 和 c-Met 表达而变化，但 HER2 阳性组表现出无进展生存期较差的趋势（HR = 1.90；95% CI，0.56- 6.41；p = 0.166）。这项研究强调了 EGFR、HER2 和 c-Met 作为 AAC 个性化治疗靶点的潜力，需要进一步研究来评估靶向治疗。

Adenocarcinoma of the ampulla of Vater (AAC) is a rare malignancy with heterogeneous tumors arising from various histologic subtypes, necessitating new therapeutic strategies. This study examines epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and c-Met expression in AAC, given their potential as druggable targets. Among 87 patients who underwent curative resection, EGFR overexpression was found in 87.4%, HER2 in 11.5%, and c-Met in 50%. EGFR overexpression was more common in the pancreatobiliary subtype (p = 0.018) and associated with a higher histologic grade (p = 0.008). HER2 did not correlate with clinicopathological features, while c-Met was more common in node-negative groups (p = 0.004) and often co-expressed with EGFR (p = 0.049). EGFR-positive patients had worse disease-free (HR = 2.89; 95% CI, 1.35-6.20; p = 0.061) and overall survival (HR = 6.89; 95% CI, 2.94-16.2; p = 0.026) than EGFR-negative patients. HER2-positive AAC showed a trend towards shorter survival, although not statistically significant, and c-Met had no impact on survival outcomes. In the context of systemic disease, survival outcomes did not vary according to EGFR, HER2, and c-Met expression, but the HER2-positive group showed a trend towards inferior progression-free survival (HR = 1.90; 95% CI, 0.56-6.41; p = 0.166). This study underscores the potential of EGFR, HER2, and c-Met as targets for personalized therapy in AAC, warranting further research to evaluate targeted treatments.